Effectively nothing acutely — and that's the design, not a flaw. Spermidine acts on cellular-quality-control machinery over weeks-to-months. No acute cognitive, mood, energy, or sleep effect at supplemental doses.

What users do report (dopamine.club n=139 + Oxford Healthspan/SpermidineLIFE testimonials):

• Day 1-7: Nothing. Occasional mild GI if wheat-germ extract on empty stomach.
• Week 2-4: Still nothing felt — common dropout window.
• Month 1-3: ~30% report faint sleep-depth/recovery improvements; confounded by placebo + lifestyle.
• Month 3-6: Some report improved nail growth, hair quality, skin texture (time course matches epithelial stem cell turnover).
• Month 6+: "I don't feel different, but my labs trend better" — typical long-horizon framing.

Almost never reported: stimulation, alertness, focus, motivation, sedation, brain fog, anxiety, headache, insomnia. Community data shows nausea/insomnia/brain-fog at n=2 each across 139 reports — noise floor.

Dylan-specific: If you want felt cognitive enhancement, this is the wrong compound — modafinil sits at the opposite end of the felt-effect axis. Pick spermidine like fish oil: for 5-20-year-horizon mechanism, not for Tuesday-afternoon feel. Adherence is the real risk because the feedback loop is invisible — food-bias toward aged cheese + mushrooms gets you the same mechanism with the bonus of tasting like something.

• Tolerance buildup: None expected and none demonstrated. Mechanism is enzyme-modulation (EP300 inhibition) + obligate substrate-feeding (hypusination of eIF5A) + chromatin-level histone-deacetylation effects — no receptor-level adaptation, no transporter downregulation reported. 12-month SmartAge trial showed no efficacy attenuation over the course of the study (efficacy was null throughout, not "early benefit then tolerance"). The 28-day 40 mg/day Soda 2024 trial showed plasma polyamines didn't rise much — but that's homeostatic regulation, not tolerance to a felt effect.
• Recommended cycle: Daily, indefinitely, no cycling. The autophagy + hypusination effect integrates over weeks-months. Stopping reverses the benefit on a similar timescale — typical of chronic-effect supplements (fish oil, vitamin D, magnesium) and unlike receptor-driven compounds (modafinil, caffeine).
• Reset protocol if needed: Not applicable. There's nothing to reset.
• Stopping considerations: If you stop, expect endogenous spermidine to drift back toward your unsupplemented baseline over 2-4 weeks. No withdrawal syndrome, no rebound — just gradual loss of whatever cellular benefit had accrued.

Synergistic with

• NAC: Proteostasis from different angles (NAC = redox/glutathione; spermidine = degradation/autophagy). No enzyme overlap. V4-canonical.
• apigenin: Cleanest pair in the longevity tier — apigenin (CD38 inhibition → NAD+ preservation + senomorphic) + spermidine (autophagy/hypusination). Both daily-safe, both cheap, mechanism-orthogonal. Bryan Johnson + Sinclair both run this.
• urolithin-A: Direct PINK1/Parkin mitophagy via separate mechanism. Preclinical work suggests additive mitophagy. No human combo data.
• rapamycin: mTORC1 inhibition (master autophagy brake) vs spermidine's EP300/hypusination (mTOR-independent) — non-overlapping. Theoretically additive but rapamycin alone saturates autophagy induction. Out of Dylan's stack regardless.
• TRF / caloric restriction: Most mechanistically grounded co-intervention. Hofer 2024 — fasting requires polyamine surge for its longevity benefit. For Dylan running TRF: supplemental marginal benefit reduced vs non-fasters.
• DHA, resveratrol, metformin, MOTS-c, SS-31: No interaction signal in any direction. Different axes, occasionally complementary.

Avoid

• DFMO (eflornithine, Rx): Direct antagonism — DFMO blocks ODC1 to deplete polyamines for tumor suppression. Don't stack.
• High-dose putrescine/ornithine supplements: Redundant upstream precursor stacking.
• Active chemotherapy / immune checkpoint therapy: Consult oncologist — theoretical interaction via tumor-microenvironment polyamine story.
• Pregnancy/breastfeeding: Insufficient data; endogenous polyamines critical in fetal development.

Neutral / safe (Dylan's stack)

All V4 (NAC, citicoline, magnesium, fish oil, PS, rhodiola, theanine, glycine, D3, curcumin, beta-alanine, vit C, creatine) and V5 candidates (modafinil, bromantane, Adamax/Semax, Selank, ALCAR, taurine, astaxanthin, tryptophan) — no concerns. Community-data "caution" flag for modafinil + spermidine (NMDA polyamine-site modulation) is animal-model extrapolation; modafinil doesn't even act there. Disregard. BPC-157/TB-500 elbow protocol — complementary if anything.

Minimal across the board. Spermidine is an endogenous metabolite present in every human cell at every supplemental dose; doesn't meaningfully inhibit/induce CYP enzymes, doesn't compete at major drug transporters. The dopamine.club community table lists ~50 paired entries — most "safe", "caution" entries are largely AI-seeded extrapolations from in vitro receptor data.

Real (mechanism-grounded)

• DFMO (eflornithine, Rx): Direct antagonism. DFMO inhibits ODC1 to deplete polyamines for tumor-suppressive effect. Don't combine. Not relevant for Dylan.
• Active chemotherapy / immune checkpoint therapy: Theoretical concern from tumor-microenvironment polyamine work (PNAS 2305245120, JCI 177824). No clinical confirmation. Consult oncologist if applicable.
• Long-course antibiotics: Gut microbiome produces ~30-50% of luminal polyamines; antibiotic disruption may shift the supplementation calculus. No clinical guidance exists.

Probably-fine but noted

• Gabapentin/pregabalin: In vitro polyamines modulate α2δ-1 binding site; at supplemental doses vs gabapentin's mg-gram dosing, clinical relevance ≈ 0.
• Sildenafil: Speculative NO-donor extrapolation from spermine-NONOate work; no clinical signal.
• MAOIs (phenelzine, tranylcypromine): Catabolic enzymes (PAO, SMOX) largely non-overlapping with MAO-A/B. Selegiline at MAO-B-selective doses — no concern.

Genuinely no concern

Immunosuppressants, anticoagulants (warfarin, apixaban), hormonal therapy (no aromatase activity unlike apigenin), modafinil + other V5 cognitive levers (despite scattered AI-seeded flags), benzodiazepines, SSRI/SNRI, statins/antihypertensives, metformin/GLP-1 agonists, vaccines, antifungals.

For Dylan: clean. No interaction concerns with V4, V5, BPC-157/TB-500, modafinil, or anything else planned. Spermidine is one of the most pharmacologically inert "active" supplements on the market.

Limited actionable PGx. Spermidine biology is highly conserved across organisms; humans show less between-individual variability than for receptor-based drugs. The variants below have biological plausibility but minimal published dosing guidance — orienting, not actionable.

• ODC1 (rate-limiting polyamine synthesis): Multiple SNPs with modest effects on baseline polyamine levels + cancer-susceptibility associations. Theoretical: low-activity carriers may benefit more from exogenous spermidine. No clinical study has stratified response by ODC1 genotype.
• SMS (spermine synthase): Loss-of-function causes Snyder-Robinson syndrome (rare X-linked ID) — pathological, unmodifiable. Common variants unstudied for supplementation.
• SMOX (spermine oxidase): Upregulated in inflammation; variants linked to neurodegeneration risk. No supplementation guidance.
• AOC1 (DAO): Low-activity carriers (~10-20%) — heavy dietary polyamine load (natto + aged cheese, 50+ mg/day) can worsen histamine-intolerance symptoms. Supplemental 1-3 mg/day too low to matter. If June 2026 23andMe shows AOC1 risk variants + Dylan develops HIT signal on food-stacking — switch to synthetic supplemental.
• MTHFR (C677T, A1298C): Polyamine synthesis interlocks with the methionine cycle (SAM → dcSAM → spermidine). Severe variants could throttle endogenous flux — supplementation bypasses the bottleneck. Modest upweight for supplementation in severe poor methylators.
• COMT, CYP2D6, CYP3A4: No actionable spermidine interactions — not a CYP substrate, not a CYP inhibitor/inducer.

When Dylan's 23andMe lands (~June 2026): No spermidine-specific decision points that flip the verdict. AOC1 status is a minor flag for food-stack vs synthetic preference; MTHFR severe variant slightly upweights supplementation. Neither moves verdict from OPTIONAL-ADD.

Recommendation for Dylan: If adding, Double Wood ($13-25/mo) or Toniiq ($8-15/mo, gluten-free synthetic) are best price-performance. Premium SpermidineLIFE or Primeadine don't deliver clinically meaningful per-mg advantage — the wheat-germ "matrix effect" has not been shown to outperform pure synthetic in any head-to-head. Better still: bias diet toward aged cheese + mushrooms + soy/natto and skip the supplement. The epidemiology is on food intake (Bratislava cohort dietary FFQ data), not on pills, and the 2024 Soda safety RCT showed that even 40 mg/day supplemental spermidine barely moves circulating polyamines — implying homeostatic regulation caps absorption of bolus doses while distributed dietary intake throughout the day may achieve better tissue exposure.

Sourcing reliability ranking (2026-05):

1. Toniiq / Double Wood / NusaPure (iHerb or direct): clean synthetic, transparent COA, gluten-free options.
2. SpermidineLIFE / Oxford Healthspan Primeadine GF: premium wheat-germ, higher reputational credibility, premium price.
3. iHerb generic SKUs: variable dose-per-cap, check label carefully — some sell "wheat germ powder" with negligible standardized spermidine content.
4. Food stack (aged Parmesan, shiitake, natto, wheat germ): cheapest, best-evidenced, requires food-prep effort.

Avoid: non-standardized "polyamine blends" that list "putrescine + spermidine + spermine" without per-mg spermidine quantification. The product industry uses "polyamine" without spermidine accountability to inflate marketing claims while underdosing the active compound.

• Baseline (before starting): Not strictly necessary. If running a longevity panel anyway (Dylan is, via June 2026 bloodwork pipeline): hs-CRP, IL-6, TNF-α (SmartAge showed trend-level reduction); fasting glucose, HbA1c (CR-mimetic context); lipid panel + ApoB (Sinclair claims fasting-like LDL/glucose reduction); ALT, AST, GGT (NAFLD-relevant).
• During use: Subjective is the main channel — no acute felt signal. Track via Oura/Whoop multi-month trend (sleep depth, HRV), perceived recovery after training, nail/hair quality. Annual bloodwork: re-check inflammation markers — most likely to show subtle systemic shift. Expect noise to dominate signal at 1-3 mg/day.
• Optional / aspirational (research-grade, mostly unavailable): Serum spermidine ($100-200 commercial — interpretability limited per Soda 2024 homeostatic finding); plasma polyamines; PBMC autophagy markers (LC3-II/p62 — research-grade); eIF5A hypusination assay (most direct, research-only); mitochondrial function panels (some longevity clinics).
• Post-cycle: N/A — daily protocol, no cycling, no withdrawal.